CJC-1295
Also known as · Modified GRF 1-29 · DAC
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
A long-acting GHRH analog (with DAC) that stimulates pulsatile growth-hormone release. Often stacked with Ipamorelin.
Binds GHRH receptors on pituitary somatotrophs to trigger endogenous GH; the DAC variant extends half-life via albumin binding.
1–2 mg subQ weekly, frequently combined with Ipamorelin 200–300 mcg 1–3× daily.
Reconstituted: refrigerated, ~30 days. Lyophilized: long-term stable.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
Ipamorelin
A selective ghrelin-receptor agonist that triggers GH release without raising cortisol or prolactin. Cleaner profile than older GHRPs.
Sermorelin
A GHRH (1-29) analog historically prescribed to assess and stimulate growth-hormone secretion. Short-acting and biomimetic.
Tesamorelin
A stabilized GHRH analog FDA-approved to reduce visceral adipose tissue in HIV-associated lipodystrophy; studied for visceral fat more broadly.